Skip to main content
NCBI home page
British Journal of Pharmacology logoLink to British Journal of Pharmacology
. 1996 Aug;118(7):1717–1726. doi: 10.1111/j.1476-5381.1996.tb15597.x

Analysis of variation in L-365,260 competition curves in radioligand binding assays.

E A Harper 1, S P Roberts 1, N P Shankley 1, J W Black 1
PMCID: PMC1909838  PMID: 8842437

Abstract

1. For several years, we have used the cholecystokinin (CCK)B/gastrin receptor selective antagonist, L-365,260, as a reference compound in a variety of studies in CCKB/gastrin receptor radioligand binding assays. Here, we have analysed the competition curve data sets obtained between L-365,260 and [125I]-BH-CCK8S in guinea-pig gastric gland and mouse and rat cerebral cortex preparations. 2. Competition curves obtained for L-365,260 in the mouse cortex assay were not different from rectangular hyperbolae (slope = 1.01 +/- 0.02) implying the presence of a single population of binding sites (pKI = 8.41 +/- 0.01; data from 47 experiments, slope constrained to unity). However, in the rat cortex and guinea-pig gastric gland assays, the mean slope of the competition curves was significantly less than one and the mean apparent pKI significantly lower than that obtained in the mouse cortex (slope = 0.85 +/- 0.03, 0.90 +/- 0.03; apparent pKI = 7.98 +/- 0.05, 8.07 +/- 0.05; 48 and 45 experiments, in rat and guinea-pig, respectively). The distribution of the individual pKI and slope estimates of the competition curves in these two assays was consistent with expectations for the variable expression (in terms of absolute number and proportion) of two binding sites. The two sites were characterized by pKI values for L-365,260 of 8.50 +/- 0.04 and 8.48 +/- 0.04 for the high affinity site and 7.32 +/- 0.04 and 7.22 +/- 0.06 for the low affinity site in guinea-pig and rat, respectively. 3. The affinity estimates for L-365,260, although obtained on different tissues, are consistent with data obtained from the analysis of L-365,260 antagonism of pentagastrin-stimulated responses in mouse and rat stomach (acid secretion) and guinea-pig gastric muscle (isotonic contraction) assays. To this extent, these data suggest the existence of two CCKB/gastrin receptor subtypes.

Full text

PDF
1717

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Beinborn M., Lee Y. M., McBride E. W., Quinn S. M., Kopin A. S. A single amino acid of the cholecystokinin-B/gastrin receptor determines specificity for non-peptide antagonists. Nature. 1993 Mar 25;362(6418):348–350. doi: 10.1038/362348a0. [DOI] [PubMed] [Google Scholar]
  2. Bertrand P., Böhme G. A., Durieux C., Guyon C., Capet M., Jeantaud B., Boudeau P., Ducos B., Pendley C. E., Martin G. E. Pharmacological properties of ureido-acetamides, new potent and selective non-peptide CCKB/gastrin receptor antagonists. Eur J Pharmacol. 1994 Sep 12;262(3):233–245. doi: 10.1016/0014-2999(94)90737-4. [DOI] [PubMed] [Google Scholar]
  3. Bousso-Mittler D., Galron R., Sokolovsky M. Endothelin/sarafotoxin receptor heterogeneity: evidence for different glycosylation in receptors from different tissues. Biochem Biophys Res Commun. 1991 Aug 15;178(3):921–926. doi: 10.1016/0006-291x(91)90979-h. [DOI] [PubMed] [Google Scholar]
  4. Chang R. S., Lotti V. J., Keegan M. E., Kunkel K. A. Characterization of [3H]pentagastrin binding in guinea pig gastric glands--an alternative convenient ligand for receptor binding assay. Biochem Biophys Res Commun. 1986 Jan 29;134(2):895–899. doi: 10.1016/s0006-291x(86)80504-6. [DOI] [PubMed] [Google Scholar]
  5. Cheng Y., Prusoff W. H. Relationship between the inhibition constant (K1) and the concentration of inhibitor which causes 50 per cent inhibition (I50) of an enzymatic reaction. Biochem Pharmacol. 1973 Dec 1;22(23):3099–3108. doi: 10.1016/0006-2952(73)90196-2. [DOI] [PubMed] [Google Scholar]
  6. Clark C. R., Daum P., Hughes J. A study of the cerebral cortex cholecystokinin receptor using two radiolabelled probes: evidence for a common CCK 8 and CCK 4 cholecystokinin receptor binding site. J Neurochem. 1986 Apr;46(4):1094–1101. doi: 10.1111/j.1471-4159.1986.tb00623.x. [DOI] [PubMed] [Google Scholar]
  7. Corp E. S., McQuade J., Moran T. H., Smith G. P. Characterization of type A and type B CCK receptor binding sites in rat vagus nerve. Brain Res. 1993 Sep 24;623(1):161–166. doi: 10.1016/0006-8993(93)90024-h. [DOI] [PubMed] [Google Scholar]
  8. Denyer J., Gray J., Wong M., Stolz M., Tate S. Molecular and pharmacological characterization of the human CCKB receptor. Eur J Pharmacol. 1994 Jun 15;268(1):29–41. doi: 10.1016/0922-4106(94)90117-1. [DOI] [PubMed] [Google Scholar]
  9. Durieux C., Ruiz-Gayo M., Corringer P. J., Bergeron F., Ducos B., Roques B. P. [3H]pBC 264, a suitable probe for studying cholecystokinin-B receptors: binding characteristics in rodent brains and comparison with [3H]SNF 8702. Mol Pharmacol. 1992 Jun;41(6):1089–1095. [PubMed] [Google Scholar]
  10. Galas M. C., Bernad N., Martinez J. Pharmacological studies on CCKB receptors in guinea pig synaptoneurosomes. Eur J Pharmacol. 1992 May 12;226(1):35–41. doi: 10.1016/0922-4106(92)90080-f. [DOI] [PubMed] [Google Scholar]
  11. Galleyrand J. C., Lima-Leite A. C., Lallement J. C., Lignon M. F., Bernad N., Fulcrand P., Martinez J. Synthesis and characterization of a new labeled gastrin ligand, 125-I-BH-[Leu15]-gastrin-(5-17), on binding to canine fundic mucosal cells and Jurkat cells. Int J Pept Protein Res. 1994 Oct;44(4):348–356. doi: 10.1111/j.1399-3011.1994.tb01019.x. [DOI] [PubMed] [Google Scholar]
  12. Goldstein A., Barrett R. W. Ligand dissociation constants from competition binding assays: errors associated with ligand depletion. Mol Pharmacol. 1987 Jun;31(6):603–609. [PubMed] [Google Scholar]
  13. Grigoriadis G., Stewart A. G. Albumin inhibits platelet-activating factor (PAF)-induced responses in platelets and macrophages: implications for the biologically active form of PAF. Br J Pharmacol. 1992 Sep;107(1):73–77. doi: 10.1111/j.1476-5381.1992.tb14465.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  14. Hughes J., Boden P., Costall B., Domeney A., Kelly E., Horwell D. C., Hunter J. C., Pinnock R. D., Woodruff G. N. Development of a class of selective cholecystokinin type B receptor antagonists having potent anxiolytic activity. Proc Natl Acad Sci U S A. 1990 Sep;87(17):6728–6732. doi: 10.1073/pnas.87.17.6728. [DOI] [PMC free article] [PubMed] [Google Scholar]
  15. Hull R. A., Shankley N. P., Harper E. A., Gerkowitch V. P., Black J. W. 2-Naphthalenesulphonyl L-aspartyl-(2-phenethyl)amide (2-NAP)--a selective cholecystokinin CCKA-receptor antagonist. Br J Pharmacol. 1993 Mar;108(3):734–740. doi: 10.1111/j.1476-5381.1993.tb12870.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  16. Hunter J. C., Suman-Chauhan N., Meecham K. G., Dissanayake V. U., Hill D. R., Pritchard M. C., Kneen C. O., Horwell D. C., Hughes J., Woodruff G. N. [3H]PD 140376: a novel and highly selective antagonist radioligand for the cholecystokininB/gastrin receptor in guinea pig cerebral cortex and gastric mucosa. Mol Pharmacol. 1993 Apr;43(4):595–602. [PubMed] [Google Scholar]
  17. Inomoto Y., Kinoshita Y., Nakamura A., Arima N., Yamashita Y., Nakata H., Yamamura Y., Hosoda S., Chiba T. Characterization of gastrin/CCK receptors on gastric carcinoid tumor membrane of Mastomys natalensis. Regul Pept. 1993 Feb 18;43(3):149–158. doi: 10.1016/0167-0115(93)90149-3. [DOI] [PubMed] [Google Scholar]
  18. Jagerschmidt A., Popovici T., O'Donohue M., Roques B. P. Identification and characterization of various cholecystokinin B receptor mRNA forms in rat brain tissue and partial determination of the cholecystokinin B receptor gene structure. J Neurochem. 1994 Oct;63(4):1199–1206. doi: 10.1046/j.1471-4159.1994.63041199.x. [DOI] [PubMed] [Google Scholar]
  19. Kalindjian S. B., Bodkin M. J., Buck I. M., Dunstone D. J., Low C. M., McDonald I. M., Pether M. J., Steel K. I. A new class of non-peptidic cholecystokinin-B/gastrin receptor antagonists based on dibenzobicyclo[2.2.2]octane. J Med Chem. 1994 Oct 28;37(22):3671–3673. doi: 10.1021/jm00048a001. [DOI] [PubMed] [Google Scholar]
  20. Kleveland P. M., Waldum H. L. The gastrin receptor assay. Scand J Gastroenterol Suppl. 1991;180:62–69. doi: 10.3109/00365529109093180. [DOI] [PubMed] [Google Scholar]
  21. Knapp R. J., Vaughn L. K., Fang S. N., Bogert C. L., Yamamura M. S., Hruby V. J., Yamamura H. I. A new, highly selective CCK-B receptor radioligand ([3H][N-methyl-Nle28,31]CCK26-33): evidence for CCK-B receptor heterogeneity. J Pharmacol Exp Ther. 1990 Dec;255(3):1278–1286. [PubMed] [Google Scholar]
  22. Kopin A. S., Lee Y. M., McBride E. W., Miller L. J., Lu M., Lin H. Y., Kolakowski L. F., Jr, Beinborn M. Expression cloning and characterization of the canine parietal cell gastrin receptor. Proc Natl Acad Sci U S A. 1992 Apr 15;89(8):3605–3609. doi: 10.1073/pnas.89.8.3605. [DOI] [PMC free article] [PubMed] [Google Scholar]
  23. Kuwahara T., Kudoh T., Nagase H., Takamiya M., Nakano A., Ohtsuka T., Yoshizaki H., Arisawa M. Tetronothiodin, a novel CCKB receptor ligand, antagonizes cholecystokinin-induced Ca2+ mobilization in a pituitary cell line. Eur J Pharmacol. 1992 Oct 6;221(1):99–105. doi: 10.1016/0014-2999(92)90777-2. [DOI] [PubMed] [Google Scholar]
  24. Kwatra M. M., Hosey M. M. Phosphorylation of the cardiac muscarinic receptor in intact chick heart and its regulation by a muscarinic agonist. J Biol Chem. 1986 Sep 25;261(27):12429–12432. [PubMed] [Google Scholar]
  25. Lee Y. M., Beinborn M., McBride E. W., Lu M., Kolakowski L. F., Jr, Kopin A. S. The human brain cholecystokinin-B/gastrin receptor. Cloning and characterization. J Biol Chem. 1993 Apr 15;268(11):8164–8169. [PubMed] [Google Scholar]
  26. Lignon M. F., Bernad N., Martinez J. Cholecystokinin increases intracellular Ca2+ concentration in the Human JURKAT T Lymphocyte cell line. Eur J Pharmacol. 1993 May 15;245(3):241–246. doi: 10.1016/0922-4106(93)90103-g. [DOI] [PubMed] [Google Scholar]
  27. Lignon M. F., Bernad N., Martinez J. Pharmacological characterization of type B cholecystokinin binding sites on the human JURKAT T lymphocyte cell line. Mol Pharmacol. 1991 May;39(5):615–620. [PubMed] [Google Scholar]
  28. Lotti V. J., Chang R. S. A new potent and selective non-peptide gastrin antagonist and brain cholecystokinin receptor (CCK-B) ligand: L-365,260. Eur J Pharmacol. 1989 Mar 21;162(2):273–280. doi: 10.1016/0014-2999(89)90290-2. [DOI] [PubMed] [Google Scholar]
  29. Magous R., Galleyrand J. C., Bali J. P. Common or distinct receptors for gastrin and cholecystokinin in gastric mucosa? Biochim Biophys Acta. 1989 Mar 6;1010(3):357–362. doi: 10.1016/0167-4889(89)90062-1. [DOI] [PubMed] [Google Scholar]
  30. McIntyre P., Phillips E., Skidmore E., Brown M., Webb M. Cloned murine bradykinin receptor exhibits a mixed B1 and B2 pharmacological selectivity. Mol Pharmacol. 1993 Aug;44(2):346–355. [PubMed] [Google Scholar]
  31. Nishida A., Miyata K., Tsutsumi R., Yuki H., Akuzawa S., Kobayashi A., Kamato T., Ito H., Yamano M., Katuyama Y. Pharmacological profile of (R)-1-[2,3-dihydro-1-(2'-methylphenacyl)-2-oxo- 5-phenyl-1H-1,4-benzodiazepin-3-yl]-3-(3-methylphenyl)urea (YM022), a new potent and selective gastrin/cholecystokinin-B receptor antagonist, in vitro and in vivo. J Pharmacol Exp Ther. 1994 May;269(2):725–731. [PubMed] [Google Scholar]
  32. Ohtsuka T., Kudoh T., Shimma N., Kotaki H., Nakayama N., Itezono Y., Fujisaki N., Watanabe J., Yokose K., Seto H. Tetronothiodin, a novel cholecystokinin type-B receptor antagonist produced by Streptomyces sp. J Antibiot (Tokyo) 1992 Jan;45(1):140–143. doi: 10.7164/antibiotics.45.140. [DOI] [PubMed] [Google Scholar]
  33. Patel M., Spraggs C. F. Functional comparisons of gastrin/cholecystokinin receptors in isolated preparations of gastric mucosa and ileum. Br J Pharmacol. 1992 Jun;106(2):275–282. doi: 10.1111/j.1476-5381.1992.tb14328.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  34. Pendley C. E., Fitzpatrick L. R., Ewing R. W., Molino B. F., Martin G. E. The gastrin/cholecystokinin-B receptor antagonist L-365,260 reduces basal acid secretion and prevents gastrointestinal damage induced by aspirin, ethanol and cysteamine in the rat. J Pharmacol Exp Ther. 1993 Jun;265(3):1348–1354. [PubMed] [Google Scholar]
  35. Pisegna J. R., de Weerth A., Huppi K., Wank S. A. Molecular cloning of the human brain and gastric cholecystokinin receptor: structure, functional expression and chromosomal localization. Biochem Biophys Res Commun. 1992 Nov 30;189(1):296–303. doi: 10.1016/0006-291x(92)91557-7. [DOI] [PMC free article] [PubMed] [Google Scholar]
  36. Praissman M., Walden M. The binding characteristics of 125I-gastrin and 125I-CCK8 to guinea pig fundic gastric glands differ: is there more than one binding site for peptides of the CCK-gastrin family? Biochem Biophys Res Commun. 1984 Sep 17;123(2):641–647. doi: 10.1016/0006-291x(84)90277-8. [DOI] [PubMed] [Google Scholar]
  37. Rubin N. H., Singh P., Alinder G., Greeley G. H., Jr, Rayford P. L., Rietveld W. J., Thompson J. C. Circadian rhythms in gastrin receptors in rat fundic stomach. Dig Dis Sci. 1988 Aug;33(8):931–937. doi: 10.1007/BF01535987. [DOI] [PubMed] [Google Scholar]
  38. Smith A. J., Patel S., Freedman S. B. Characterisation of CCKB receptors on GH3 pituitary cells: receptor activation is linked to Ca2+ mobilisation. Eur J Pharmacol. 1994 Apr 15;267(2):215–223. doi: 10.1016/0922-4106(94)90173-2. [DOI] [PubMed] [Google Scholar]
  39. Smith J. P., Rickabaugh C. A., McLaughlin P. J., Zagon I. S. Cholecystokinin receptors and PANC-1 human pancreatic cancer cells. Am J Physiol. 1993 Jul;265(1 Pt 1):G149–G155. doi: 10.1152/ajpgi.1993.265.1.G149. [DOI] [PubMed] [Google Scholar]
  40. Song I., Brown D. R., Wiltshire R. N., Gantz I., Trent J. M., Yamada T. The human gastrin/cholecystokinin type B receptor gene: alternative splice donor site in exon 4 generates two variant mRNAs. Proc Natl Acad Sci U S A. 1993 Oct 1;90(19):9085–9089. doi: 10.1073/pnas.90.19.9085. [DOI] [PMC free article] [PubMed] [Google Scholar]
  41. Soumarmon A., Cheret A. M., Lewin M. J. Localization of gastrin receptors in intact isolated and separated rat fundic cells. Gastroenterology. 1977 Oct;73(4 Pt 2):900–903. [PubMed] [Google Scholar]
  42. Wank S. A., Pisegna J. R., de Weerth A. Brain and gastrointestinal cholecystokinin receptor family: structure and functional expression. Proc Natl Acad Sci U S A. 1992 Sep 15;89(18):8691–8695. doi: 10.1073/pnas.89.18.8691. [DOI] [PMC free article] [PubMed] [Google Scholar]
  43. Wells J. W., Birdsall N. J., Burgen A. S., Hulme E. C. Competitive binding studies with multiple sites. Effects arising from depletion of the free radioligand. Biochim Biophys Acta. 1980 Oct 15;632(3):464–469. doi: 10.1016/0304-4165(80)90242-1. [DOI] [PubMed] [Google Scholar]
  44. Williams J. A., Bailey A. C., Roach E. Temperature dependence of high-affinity CCK receptor binding and CCK internalization in rat pancreatic acini. Am J Physiol. 1988 Apr;254(4 Pt 1):G513–G521. doi: 10.1152/ajpgi.1988.254.4.G513. [DOI] [PubMed] [Google Scholar]

Articles from British Journal of Pharmacology are provided here courtesy of The British Pharmacological Society

RESOURCES